Relaxin-2 Expression in Oral Squamous Cell Carcinoma
The International Journal of Biological Markers · 2016-07 · 31 (3) · 324-329
DOI: 10.5301/jbm.5000219 ↗Kurz gefasst
Fachartikel in der Zeitschrift The International Journal of Biological Markers, online erschienen am 30.07.2016. Verfasst von Gino Marioni und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences DNS, Otolaryngology Section, Padua University, Padua - Italy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Background
When advanced, oral squamous cell carcinoma (OSCC) may involve adjacent non-epithelial structures, and the prognosis is worse for bone invasion. Human relaxin-2 is a peptide hormone that has recently been associated with cancer. It can induce human osteoclast differentiation and activation, suggesting a role in tumor-driven osteolysis. This study was a preliminary assessment of the prognostic role of relaxin-2 in surgical specimens of OSCC tissue and adjacent but uninvolved mandibular/maxillary bone.
Methods
Relaxin-2 immunohistochemical expression and reaction intensity were assessed in tumor and uninvolved adjacent mandibular/maxillary bone specimens from 23 operated OSCC patients.
Results
All OSCC specimens were positive for relaxin-2. The intensity of its reaction in OSCC correlated significantly with the pattern of the tumor's invasion front (p = 0.02), being higher with the infiltrative pattern. Mean relaxin-2 immunohistochemical expression was higher in patients whose OSCC recurred after treatment than those experiencing no recurrence (81.3% ± 22.6% vs. 59.5% ± 29.7%, respectively). A significant direct association emerged between relaxin-2 expression in OSCC specimens and recurrence rate (p = 0.049).
Conclusions
Relaxin-2 expression in OSCC should be further investigated as a potentially useful marker for identifying patients at higher risk of recurrence, who might benefit from closer follow-up and more aggressive adjuvant therapy. In other oncological settings, increasing evidence of relaxin being produced by cancer cells is prompting efforts to synthesize human relaxin-2 analogs capable of acting as antagonists and limiting tumor growth.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurosciences DNS, Otolaryngology Section, Padua University, Padua - Italy.
- Department of Medicine DIMED, Padua University, Padua - Italy.
- Department of Neurosciences DNS, Maxillofacial Surgery Unit, Padua University, Padua - Italy.
- Maxillofacial Surgery Unit, Treviso Hospital, Treviso - Italy.
Zitieren
APA
Marioni, G., Di Carlo, R., Ottaviano, G., Cappellesso, R., Bedogni, A., Marchese-Ragona, R., Stritoni, P., Rossi, M., Zanoletti, E., Favaretto, N., Valentini, E., Apolloni, F., Giacomelli, L., Martini, A., & Blandamura, S. (2016). Relaxin-2 Expression in Oral Squamous Cell Carcinoma. The International Journal of Biological Markers, 31(3), 324-329. https://doi.org/10.5301/jbm.5000219
Vancouver
Marioni G, Di Carlo R, Ottaviano G, Cappellesso R, Bedogni A, Marchese-Ragona R, et al. Relaxin-2 Expression in Oral Squamous Cell Carcinoma. The International Journal of Biological Markers. 2016;31(3):324-329. doi:10.5301/jbm.5000219
BibTeX
@article{Marioni2016,
author = {Marioni, Gino and Di Carlo, Roberto and Ottaviano, Giancarlo and Cappellesso, Rocco and Bedogni, Alberto and Marchese-Ragona, Rosario and Stritoni, Paola and Rossi, Marco and Zanoletti, Elisabetta and Favaretto, Niccolò and Valentini, Elisa and Apolloni, Federico and Giacomelli, Luciano and Martini, Alessandro and Blandamura, Stella},
title = {Relaxin-2 Expression in Oral Squamous Cell Carcinoma},
journal = {The International Journal of Biological Markers},
year = {2016},
volume = {31},
number = {3},
pages = {324--329},
doi = {10.5301/jbm.5000219}
}
EUVIMED